Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PERFORM: An EPidEmiological, PRospective Cohort Study to Generate Real-world Evidence in Patients With HR+/HER2- Advanced Breast Cancer Treated in the First Line Setting as Per Current Standard Of Care With an EndocRine-based Palbociclib CoMbination Therapy

NCT04767594 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT04767594
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04767594 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PERFORM: An EPidEmiological, PRospective Cohort Study to Generate Real-world Evidence in Patients With HR+/HER2- Advanced Breast Cancer Treated in the First Line Setting as Per Current Standard Of Care With an EndocRine-based Palbociclib CoMbination Therapy
Lead sponsor
Pfizer
Phase
Observational
Overall status
Active, not recruiting
Start date
October 27, 2020
Completion date
April 30, 2028
Enrollment
1,407 (actual)
Sites
192

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms